Status and phase
Conditions
Treatments
About
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
Full description
A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder Twice Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal, Asthma Therapy
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subjects eligible for enrollment in the study must meet all of the following criteria:
Inclusion Criteria for Randomization
At the end of the run-in period, a subject will be eligible to enter the treatment period of the study if he/she meets the following criteria at Visit 3:
Exclusion criteria
NOTE: Immunotherapy for the treatment of allergies is allowed during the study provided that the treatment was initiated prior to Visit 1 and the subject is maintained on a stable regimen throughout the study period.
Administration of inhaled corticosteroids within 6 weeks of Visit 1.
Exclusion Criteria for Randomization At the end of the run-in period, a subject will not be eligible to enter the treatment period of the study if they meet any of the following criteria.
Primary purpose
Allocation
Interventional model
Masking
599 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal